betacoronavirus

Documents about betacoronavirus

• Structural and Functional Analysis of Translation Inhibition by Betacoronavirus Non-Structural Protein 1#656565EliScholar
• Vaccinating older adults against COVID-19#1461746WHO IRIS
• COVID-19 epidemiological update, edition 169, 15 July 2024#279023WHO IRIS
• A divergent betacoronavirus with a functional furin cleavage site in South American bats#358812Repositório Institucional Unesp
• Neu1 inhibition restrains BCoV replication and modulates ZBP1-dependent PANoptosis#171608HAL (France)
• Impact of COVID-19 on health professionals’ education in Eastern Mediterranean Region#649911WHO IRIS
• Clinical management of COVID-19: living guideline, June 2025#663617WHO IRIS
• Opciones terapéuticas y COVID-19: orientaciones evolutivas, 10 de noviembre de 2023#356067WHO IRIS
• WHO guidelines on the use of chest imaging in COVID-19#404869WHO IRIS
• Repurposing facilities for quarantine or isolation and management of mild COVID-19 cases#649878WHO IRIS
• COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December 2021#413792WHO IRIS
• Fourth meeting of the Technical Advisory Group on Safe Schooling during the COVID-19 Pandemic: Copenhagen, Denmark, 9 March 2021#163837WHO IRIS
• Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023#413789WHO IRIS
• Orientations évolutives concernant la prise en charge clinique de la COVID-19 : orientations évolutives, 23 novembre 2021#423687WHO IRIS
• Data protection during the coronavirus crisis#465602OpenAlex
• Revue intra-action (RIA) de la COVID-19 : modèle de note conceptuelle, 23 juillet 2020#649871WHO IRIS
• Accélérer la préparation et la riposte aux situations d’urgence sanitaire - plan d’action#184004WHO IRIS
• The will to speak out: Medical anthropologist and patient in times of COVID-19 in Peru#1416656Repositorio Institucional de la PUCP
• How US law will evaluate artificial intelligence for covid-19#964484OpenAlex
• Sustaining COVID-19 pandemic response gains in the WHO Eastern Mediterranean Region: mapping strategic opportunities and ways forward#346316WHO IRIS
• Annexes to the recommendations for use of the Biological E Limited’s Corbevax (BECOV-2) vaccine against COVID-19: grading of evidence, evidence to recommendations tables, first issued 25 September 2023#432273WHO IRIS
• Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis#481125OpenAlex
• Quais as estratégias de ventilação pulmonar na síndrome do desconforto respiratório agudo causada pela COVID-19?: estudo de revisão#1040359Repositório Institucional da UFPB
• Avaliação do impacto do tratamento com a bactéria lática Weissella paramesenteroides WpK4 na resposta imunológica desencadeada in vitro pelo SARS-CoV-2 e in vivo pela proteína N do vírus#989569Repositório Institucional da UFMG
• Responding to non-communicable diseases during and beyond the COVID-19 pandemic: examples of actions being taken by selected members of the United Nations Inter-Agency Task Force on the prevention and control of non-communicable diseases#1374903WHO IRIS
• In silico analysis of C₆₀ fullerene interaction with TMPRSS2: toward novel COVID-19 prevention approaches#463859Dbt
• Introduction of the annual report Dr Ahmed Al-Mandhari Regional Director WHO Eastern Mediterranean Region to the sixty-ninth session of the WHO Regional Committee, Cairo, Egypt, 10-13 October 2022#223734WHO IRIS
• Uso de pruebas de diagnóstico rápido de detección de antígenos del SARS-CoV-2 para el autodiagnóstico de la COVID-19: orientaciones provisionales, 9 de marzo de 2022: anexo B de la web: autodiagnóstico de la COVID-19 mediante el uso de pruebas de diagnóstico rápido de detección de antígenos: evaluación de la viabilidad entre el personal de salud y la población general en Malawi y Zimbabwe#422116WHO IRIS
• Feuille de route de l’OMS concernant l’utilisation des vaccins contre la COVID-19 dans le contexte des variants Omicron et d’une forte immunité collective : approche visant à optimiser l’impact mondial des vaccins contre la COVID-19 alors que le variant Omicron et ses sous-lignées sont les principaux variants préoccupants en circulation, compte tenu des objectifs de santé publique, de l’évolution épidémiologique et d’une immunité collective croissante, première publication : 20 octobre 2020, mise à jour : 13 novembre 2020, mise à jour : 16 juillet 2021, mise à jour : 21 janvier 2022, mise à jour : 30 mars 2023, dernière mise à jour : 10 novembre 2023#341846WHO IRIS
• Hoja de ruta de la OMS sobre el uso de las vacunas contra la COVID-19 en el contexto de la variante ómicron y de la elevada inmunidad de la población: criterio para optimizar el impacto mundial de las vacunas contra la covid-19 en un momento en que la variante ómicron y sus sublinajes son las variantes preocupantes dominantes en circulación, sobre la base de los objetivos de salud pública, las características epidemiológicas en evolución y la creciente inmunidad de la población, primera publicación: 20 de octubre de 2020, actualización: 13 de noviembre de 2020, actualización: 16 de julio de 2021, actualización: 21 de enero de 2022, actualización: 30 de marzo de 2023, actualización: 10 de noviembre de 2023#341849WHO IRIS